TLX News: Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study - 8th May 2023, 7:00am

[annb0t]

MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is investigating the efficacy of Bayer's androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation t...

>>> Read more: Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study